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ABSTRACT
Objective: To examine the association between the
experience of patient-centred care (PCC), health
behaviours and cardiovascular disease (CVD) risk
factor levels among people with type 2 diabetes.
Design: Population-based prospective cohort study.
Setting: 34 general practices in East Anglia, UK,
delivering organised diabetes care.
Participants: 478 patients recently diagnosed with
type 2 diabetes aged between 40 and 69 years enrolled
in the ADDITION-Plus trial.
Main outcome measures: Self-reported and
objectively measured health behaviours (diet, physical
activity, smoking status), CVD risk factor levels (blood
pressure, lipid levels, glycated haemoglobin, body
mass index, waist circumference) and modelled 10-
year CVD risk.
Results: Better experiences of PCC early in the course
of living with diabetes were not associated with
meaningful differences in self-reported physical activity
levels including total activity energy expenditure
(β-coefficient: 0.080 MET h/day (95% CI 0.017 to
0.143; p=0.01)), moderate-to-vigorous physical activity
(β-coefficient: 5.328 min/day (95% CI 0.796 to 9.859;
p=0.01)) and reduced sedentary time (β-coefficient:
−1.633 min/day (95% CI −2.897 to −0.368; p=0.01)).
PCC was not associated with clinically meaningful
differences in levels of high-density lipoprotein
cholesterol (β-coefficient: 0.002 mmol/L (95% CI 0.001
to 0.004; p=0.03)), systolic blood pressure
(β-coefficient: −0.561 mm Hg (95% CI −0.653 to
−0.468; p=0.01)) or diastolic blood pressure
(β-coefficient: −0.565 mm Hg (95% CI −0.654 to
−0.476; p=0.01)). Over an extended follow-up of
5 years, we observed no clear evidence that PCC was
associated with self-reported, clinical or biochemical
outcomes, except for waist circumference (β-
coefficient: 0.085 cm (95% CI 0.015 to 0.155;
p=0.02)).
Conclusions: We found little evidence that experience
of PCC early in the course of diabetes was associated
with clinically important changes in health-related
behaviours or CVD risk factors.
Trial registration number: ISRCTN99175498; Post-
results.
INTRODUCTION
Type 2 diabetes is a common condition
mostly managed in general practice. Despite
current lifestyle and medication treatments,
patients with diabetes still have high rates of
cardiovascular disease (CVD) morbidity and
mortality.1 Patient-centred care (PCC) is con-
sidered the cornerstone of UK general prac-
tice and may play an important role in the
management of CVD risk factor levels.2 By
understanding individual health beliefs, con-
sidering patient preferences and developing
mutual management plans, general practi-
tioners (GPs) may be able to positively inﬂu-
ence health behaviours such as diet, physical
activity, smoking and alcohol intake, each of
Strengths and limitations of this study
▪ Our study is the first to use objective measures
of health behaviours to examine the impact of
patient-centred care in recently diagnosed type 2
diabetes.
▪ The study duration is 5 years with high rates of
follow-up.
▪ We included a large number of general practi-
tioner (GP) surgeries that reflects the average UK
GP list size, number of doctors/nurses and dia-
betes prevalence.
▪ Patient-centred care was only measured at a
single time point.
▪ The majority of our participants were Caucasian
males with high levels of education and employ-
ment, thereby limiting the generalisability of our
findings.
Dambha-Miller H, et al. BMJ Open 2016;6:e008931. doi:10.1136/bmjopen-2015-008931 1
Open Access Research
group.bmj.com on January 15, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
which are known to inﬂuence CVD risk factor levels.3
This potentially effective and cost-effective role for GPs
in inﬂuencing patient health behaviours has recently
been emphasised in national and international health
policy.4 5 6 The majority of supporting evidence comes
from observational data reporting inverse associations
between PCC and CVD risk factor levels.7 Trial ﬁndings
have been more variable with some studies reporting no
effect from interventions promoting PCC, while others
report reduced CVD risk factor levels including glycated
haemoglobin (HbA1c), blood pressure, cholesterol and
body mass index (BMI).3 8 9 10 There is currently insufﬁ-
cient evidence to conﬁrm whether PCC inﬂuences CVD
risk factor levels among patients with diabetes, and the
mechanism to explain any associations remains unclear.
We hypothesise that the mechanism linking PCC to CVD
risk factor levels is through patient health behaviours.11
The majority of diabetes care occurs in general prac-
tice where there is increasing pressure on GP consult-
ation time. This is leading to a range of alternative
chronic disease management strategies such as more
routinised care, telehome care and remote monitoring,
each of which may diminish PCC.12 13 14 With the need
to optimise efﬁciency as well as effectiveness in diabetes
care, it is increasingly important to assess the experience
of PCC in improving disease risk. Evidence for the role
of PCC in cost-effective diabetes care is needed to
inform policy and has implications for the management
of chronic disease more widely.
We aimed to quantify the association between the
experience of PCC delivered by GPs and CVD risk factor
levels at 1-year and 5-year follow-up in a well-
characterised cohort of patients recently diagnosed with
type 2 diabetes. To enable better understanding of the
potential mechanisms underlying this association, we
also examined associations between PCC and health
behaviours.
METHODS
Study design
A detailed description of the ADDITION-Plus study design
and rationale can be found elsewhere.15 In brief,
ADDITION-Plus is a randomised-controlled trial among
34 general practices across East Anglia, UK.
ADDITION-Plus examined the efﬁcacy of a facilitator-led,
theory-based behaviour change intervention for indivi-
duals with recently diagnosed type 2 diabetes. In total,
478 out of 1109 eligible individuals agreed to participate
and were individually randomised to receive either inten-
sive treatment alone (n=239) or intensive treatment plus
a facilitator-led individual behaviour change intervention
(n=239). The trial was not designed to inﬂuence patient–
practitioner interactions and there were no differences in
PCC measures, health behaviours, CVD risk factor levels
between trial groups at 1 year, and no differences in the
proceeding multivariate analyses between trial arms.
Therefore, data for this analysis were pooled and treated
as a cohort analysis. Participants in the trial were followed
up for 5 years. All measurements were taken at baseline,
1-year and 5-year follow-up, except for objectively mea-
sured physical activity which was assessed at 1-year and
5-year follow-up, and PCC at 1-year follow-up. All partici-
pants gave written informed consent, and the study was
approved by the Eastern Multi-Centre Research Ethics
Committee (reference number 02/5/54). The trial is
registered as ISRCTN99175498.
Measurements and outcomes
Self-reported health behaviour
Physical activity and dietary intake were assessed by self-
report using the validated EPIC Physical Activity
Questionnaire (EPAQ-2) and semiquantitative food fre-
quency questionnaire.16 17 Alcohol intake and smoking
status (categorised as never smoked, ex-smoker or current
smoker) were assessed by self-report questionnaire.
Objective measures of health behaviour
Physical activity was measured using a combined heart
rate and movement sensor (Actiheart, CamNtech) worn
for at least three consecutive days, as described previ-
ously.16 Resulting time-series data were summarised into
physical activity energy expenditure (in kJ/kg/day)—a
measure of total physical activity, sedentary time (h/day)
and moderate-to-vigorous physical activity (MVPA; min/
day).18 Plasma vitamin C levels (which offer an objective
biomarker measure of fruit and vegetable intake)17 were
measured using a Fluoroskan Ascent FL ﬂuorometer.17 19
Clinical and biochemical measures
Clinical and biochemical measures were collected by
trained staff following standardised protocols, as
described elsewhere.15 Blood pressure was calculated as
the mean of three measurements using an automatic
sphygmomanometer. Body weight and height were mea-
sured in light clothing and without shoes using a scale
(SECA) and a ﬁxed rigid stadiometer, respectively.15
Venous blood samples were collected for analysis of lipid
levels and HbA1c. Modelled 10-year cardiovascular risk
was calculated using the UK Prospective Diabetes Study
(UKPDS) risk engine (V.3.0).
Patient-centred care
PCC is a challenging concept to study or measure as there
are multiple deﬁnitions and tools within the literature. At
its core, PCC seeks to encompass the management of bio-
physical markers, alongside the human experience of
disease. The consultation and relational empathy (CARE)
measure is a holistic tool that attempts to capture PCC with
a focus on the quality of consultations in terms of the
‘human’ aspects (empathic process of care). This is in
the context of a doctor–patient interaction and from the
patient’s perspective. The CARE questionnaire is a
measure that has been shown to be meaningful to patients,
acceptable and easy to complete. It has been developed
and extensively validated within the primary care setting,
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where the vast majority of type 2 diabetes care occurs in
the UK.20 The CARE measure includes 10 questions based
on a Likert scale ranging from 1 to 5. A CARE summary
measure was derived by summing the individual scores
from the 10 individual questions, with a possible range of
10–50.20 Participants completed a questionnaire on PCC
experiences in relation to their GPs over the preceding
year, in relation to diabetes care using the CARE measure
at 1-year follow-up.21
Statistical analysis
Participant characteristics were summarised at baseline,
1-year and 5-year follow-up using means (SDs) or fre-
quencies. Participants with incomplete data across time
points were excluded from the analyses. Multivariate
linear regression models were constructed to examine
the prospective associations between baseline and 1-year
follow-up, and between 1-year and 5-year follow-up
between PCC measures and: (1) change in self-reported
health behaviours; (2) change in objective health
behaviours; (3) changes in biochemical and clinical
measures; and (4) change in modelled 10-year cardiovas-
cular risk. As physical activity was not measured object-
ively at baseline, this was examined cross-sectionally at
1 year. All models were adjusted, based on a priori rea-
soning, for age, sex, socioeconomic group, ethnicity,
trial group, relevant medication use (ie, change in blood
pressure, lipid or diabetes medications). Statistical ana-
lysis was performed using STATA/SE V.13.1
(STATA-Corp, College Station, Texas, USA). Statistical
signiﬁcance was set at p<0.05.
RESULTS
Participant characteristics
Three hundred and ninety-six ADDITION-Plus partici-
pants had complete data and were included in these
analyses. Participants had a mean (SD) age of 61 (6.9)
years; the majority were Caucasian (96%) and male
(63%; table 1). Seventy-four per cent of participants
were in part-time or full-time employment and most
continued in full-time education after the age of
16 years (61%). Baseline mean (SD) HbA1c was 7.1
(1.4)% (49.7 mmol/mol) (1.3). Change in clinical and
biochemical variables at baseline, 1-year and 5-year
follow-up is summarised in table 2. Mean BMI, waist cir-
cumference, HbA1c, blood pressure and cholesterol
levels improved over the 5 years of follow-up. The mean
(SD) CARE score was 39 (9.8) at 1-year follow-up. There
were no signiﬁcant differences in age, sex, ethnicity,
employment status, social class, education, smoking
status, blood pressure, lipid proﬁle, waist circumference
and 10-year modelled cardiovascular risk between parti-
cipants with and without missing data for these analyses.
Self-reported health behaviours
Analysis of change from baseline to 1-year follow-up
showed that participants reporting better experiences of
PCC were more likely to increase their self-reported
physical activity by small amounts, including total activity
energy expenditure (β-coefﬁcient: 0.080 MET h/day
(95% CI 0.017 to 0.143), MVPA (β-coefﬁcient:
5.328 min/day (95% CI 0.796 to 9.859)), and reduce
sedentary time (β-coefﬁcient: −1.633 min/day (95% CI
−2.897 to −0.368); table 3). We observed no clear asso-
ciations between PCC and self-reported diet or alcohol
intake. Over a longer follow-up from 1 to 5 years, there
was no clear evidence that better experiences of PCC
were associated with change in self-reported physical
activity, diet or alcohol intake (table 3). We have not
reported on change in smoking status as too few (n=12)
participants quit or started smoking to enable this to be
examined.
Objective health behaviours
Over the ﬁrst year of follow-up, there was no evidence
that better experience of PCC were associated with
objectively measured physical activity or diet (fruit and
Table 1 Baseline characteristics in the ADDITION-Plus
trial cohort (n=396)
Variables Mean±SD
Sociodemographic characteristics
Male sex, n (%) 252 (63.1)
Age at baseline (years) 61 (6.9)
White ethnic origin, n (%) 379 (96)
Employed, n (%) 296 (74)
Social class, n (%)
High 170 (43.4)
Manual 173 (44.3)
Non-manual 48 (12.2)
Education, n (%)
Full-time education finished at <16 years 150 (38.4)
Full-time education finished at 16–18 years 172 (44.0)
Full-time education finished at >18 years 69 (17.6)
Medical history
History of angina, n (%) 47 (10.7)
History of hypertension, n (%) 175 (40.2)
History of any cardiovascular disease
including AF
50 (11.6)
History of myocardial infarct, n (%) 31 (7.26)
History of hypercholesterolaemia, n (%) 197 (46.9)
History of stroke, n (%) 13 (3.1)
Self-reported drug use
Any glucose-lowering drug, n (%) 126 (32)
Any antihypertensive drug, n (%) 280 (71)
Any cholesterol-lowering drug, n (%) 205 (52)
Self-reported lifestyle
Physical activity energy expenditure, mean
(SD) (kJ/kg/day)
29 (7.4)
Smoking status, n (%)
Current smoker 55 (14)
Ex-smoker 196 (49.7)
Never smoker 142 (36)
Alcohol per week (units), mean (SD) 9 (13.9)
Values are presented as mean (SD) unless specified.
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vegetable intake measured with plasma vitamin C levels).
Similarly, analysis of change between 1 and 5 years also
demonstrated no associations between PCC and object-
ively measured diet or physical activity. These results are
summarised in table 3.
Clinical and biochemical measures
Analysis of change over the ﬁrst year of follow-up
demonstrated that participants with better experiences
of PCC had marginally greater increases in high-density
lipoprotein (HDL) cholesterol (β-coefﬁcient:
0.002 mmol/L (95% CI 0.001 to 0.004)) and decreases
in both systolic blood pressure (β-coefﬁcient:
−0.561 mm Hg (95% CI −0.653 to −0.468)) and dia-
stolic blood pressure (β-coefﬁcient: −0.565 mm Hg (95%
CI −0.654 to −0.476)). As shown in table 3, there were
no other associations between baseline and 1 year in
clinical and biochemical measures. Over the longer
5-year follow-up, there were no associations between
PCC and clinical or biochemical outcomes, except for
waist circumference (β-coefﬁcient: 0.085 cm (95% CI
0.015 to 0.155)) which increased with higher PCC.
DISCUSSION
Better experience of PCC early after the diagnosis of
type 2 diabetes was associated with a small, but not
clinically meaningful change in self-reported physical
activity, time spent sedentary, and improvements in
HDL-cholesterol and blood pressure at 1-year. This was
not reﬂected in the objective measures of physical activ-
ity. Over the longer term, we found no evidence to
suggest that PCC was associated with changes in health
behaviours or CVD risk factor levels. This study provides
insufﬁcient evidence that patients recently diagnosed
with type 2 diabetes who have experiences of PCC are
more likely to have lower cardiovascular risk factor levels
via changes in patient health behaviours.
To the best of our knowledge, this is the ﬁrst study to
use objective measures of health behaviours alongside
self-reported health behaviours to quantify the impact of
experiences of PCC in a population with recently diag-
nosed type 2 diabetes. Furthermore, it includes a
relatively long duration of follow-up of 5 years. We
observed discrepancies in associations between PCC and
self-reported, and objectively measured physical activity
and diet. This highlights the potential bias associated
with patient self-report questionnaires in previous
studies. Other strengths include the use of a large
number of GP surgeries which reﬂect average UK GP list
sizes, diabetes prevalence, doctor or nurse whole time
equivalent and patient experiences of diabetes care.
Further, more than 50% of practices that were
approached agreed to participate in the original study.
The participant follow-up rate was also high at 95% at
year follow-up and 83% at the 5-year follow-up. In rela-
tion to previous literature on PCC, this cohort study also
includes a relatively large sample size. Additional
strengths include our measure of PCC; while some previ-
ous studies have used non-speciﬁc and non-validated
patient satisfaction questionnaires as a marker of PCC,
we used the validated CARE measure.8 10 21 22 The valid-
ity and reliability of the CARE measure has been exten-
sively demonstrated, and applied in over 3000 general
practice consultations in areas of high and low depriv-
ation and across multiple health conditions.
A number of limitations of our study also warrant discus-
sion. We measured PCC at a single time point at 1-year
follow-up which may explain differences between 1-year
and 5-year results. Further, because doctor–patient rela-
tionships are dynamic and are established or changed over
time,23 we were not able to examine how changes in
experiences of PCC might affect health behaviours and
CVD risk factor levels. The majority of participants were
Caucasian males with high levels of education and employ-
ment, thereby limiting the generalisability of our ﬁndings
as experiences of PCC and diabetes care may differ in a
more ethnically diverse or socially deprived populations.
The majority of participants reported high CARE scores
which, due to homogeneity, will likely have reduced our
ability to identify associations with health outcomes.
Finally, we also conducted a number of hypothesis tests
and as a result we cannot exclude the role of chance as a
plausible explanation for our ﬁndings.
Previous studies examining the association of interven-
tions to alter PCC and CVD risk factor levels in type 2
Table 2 Clinical variables of participants with complete data at all three time points
N Baseline One-year follow-up Five-year follow-up
Clinical characteristics
BMI (kg/m²) 383 32.4 (5.6) 31.8 (5.1) 31.9 (5.4)
Waist circumference (cm) 383 109.9 (13.0) 108.6 (12.8) 107.9 (13.6)
HbA1c (%), mean (SD) 387 7.1 (1.4) 6.6 (0.9) 6.9 (0.9)
Systolic blood pressure (mm Hg) 396 136.8 (19.7) 130.2(17.7) 132.2 (16.4)
Diastolic blood pressure (mm Hg) 396 80.7 (10.6) 76.4 (9.5) 73.9 (9.8)
Total cholesterol (mmol/L) 390 4.9 (1.06) 4.3 (0.8) 4.2 (0.9)
HDL-cholesterol (mmol/L) 390 1.2 (0.3) 1.2 (0.3) 1.3 (0.3)
LDL-cholesterol (mmol/L) 390 2.9 (0.9) 2.3 (0.7) 2.1 (0.7)
Values are mean (SD).
BMI, body mass index; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Table 3 Linear associations between patient-centred care and outcomes at 1- and 5-year follow-up in ADDITION-Plus cohort
Changes from 0 to 1 years of follow-up Changes from 1 to 5 years of follow-up
Variable N Coefficient 95% CI p Value Coefficient 95% CI p Value
Self-reported measures
Total activity energy expenditure (MET h/day) 371 0.080 0.017 0.143 0.01 −0.037 −0.318 0.243 0.79
Sedentary time (min/day) 371 −1.633 −2.897 −0.368 0.01 0.014 −0.010 0.037 0.25
Moderate-to-vigorous physical activity (min/day) 371 5.328 0.796 9.859 0.01 −0.241 −0.880 0.400 0.46
Energy intake (kJ/day) 371 0.920 −3.960 5.810 0.71 0.012 0.001 0.001 0.51
Alcohol per week (units) 371 0.022 −0.037 0.081 0.47 −0.022 −0.085 0.041 0.49
Objectively measured health behaviours
Physical activity energy expenditure (kJ/kg/day)* 308 −0.001 −0.166 0.164 0.99 −0.014 0.850 −0.100 0.08
Plasma vitamin C (μmol/L) 303 −0.231 −0.462 <0.001 0.05 −0.040 −0.100 0.020 0.17
Clinical and biochemical measures
HbA1c (%)† 387 −0.006 −0.015 0.004 0.23 0.004 −0.005 0.013 0.39
Systolic blood pressure (mm Hg)‡ 396 −0.561 −0.653 −0.468 0.01 0.107 −0.053 0.267 0.19
Diastolic blood pressure (mm Hg)‡ 396 −0.565 −0.654 −0.476 0.01 0.064 −0.031 0.159 0.19
Total cholesterol (mmol/L)§ 390 0.002 −0.006 0.011 0.58 0.001 −0.008 0.010 0.83
HDL-cholesterol (mmol/L)§ 390 0.002 0.001 0.004 0.03 −0.002 −0.004 0.001 0.17
LDL-cholesterol (mmol/L)§ 390 0.007 0.001 0.014 0.07 0.001 −0.007 0.007 0.99
Waist circumference (cm) 383 −0.060 −0.120 0.011 0.07 0.085 0.015 0.155 0.02
BMI (kg/m²) 383 −0.010 −0.031 0.006 0.19 0.013 −0.010 0.036 0.27
Modelled UKPDS 10-year cardiovascular risk¶ 390 0.001 −0.001 <0.001 0.54 0.001 −0.001 0.001 0.51
*Measured at 1-year only.
†Adjusted for sex, age, ethnicity, social class and hypoglycaemic medication.
‡Adjusted for sex, age, ethnicity, social class and antihypertensive medication.
§Adjusted for sex, age, ethnicity, social class and lipid-lowering therapy.
¶Adjusted for sex, age, ethnicity, social class, lipid-lowering therapy, antihypertensive and hypoglycaemic medication.
BMI, body mass index; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; UKPDS, UK Prospective Diabetes Study.
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diabetes have reported mixed results. This may be
related to the fact that PCC is a broad term with mul-
tiple descriptions and measures, and therefore a high
level of heterogeneity exists between studies on this
subject.24 We found positive associations, albeit clinically
not meaningful, between PCC and self-reported physical
activity level, blood pressure and HDL-cholesterol, that is
—people with better PCC experiences reported being
more physically active and had higher HDL-cholesterol
levels and lower blood pressures at 1-year. This is consist-
ent with some previous observational and trial
data,22 25 26 27 28 except our study includes objective
measures and therefore overcomes some of the limita-
tions associated with previous self-reported data. Several
studies have also reported inverse associations between
PCC and non HDL-cholesterol,25 28 22 BMI,
HbA1c29 30 31 and cardiovascular risk.32 We did not
observe such associations at 1-year or 5-year
follow-up.10 25 30 Differences may have been because our
study was underpowered to detect these changes, or
might be related to our measure of PCC. Our study is
the ﬁrst to use the CARE measure as a speciﬁc marker
of PCC focusing on empathy in patients recently diag-
nosed with type 2 diabetes that were followed up over a
5-year period.20 These differences, as well as the poten-
tial role of chance, may also explain the positive, albeit
small, unexpected association between PCC and waist
circumference.
Further, baseline measures also vary across studies
which may explain differences in ﬁndings. For example,
mean HbA1c in participants in our cohort at baseline
was 7.1%. A recent large study in type 2 diabetes within
secondary care demonstrated signiﬁcant reductions in
HbA1c following a PCC intervention.31 This study sug-
gested that a PCC approach may be most effective in
improving glycaemic control when baseline HbA1c is
over 8.5%, and reported modest effects in patients with
an HbA1c below 7%. Previous studies in primary care
have similarly demonstrated a greater effect of PCC
when baseline HbA1c was high.22 29 30 33 We therefore
carried out a post hoc analysis including only partici-
pants with HbA1c over 8.5% at baseline, and found
stronger associations between PCC, physical activity, and
HbA1c, non-HDL-cholesterol and BMI, but these asso-
ciations did not reach statistical signiﬁcance, likely owing
to the reduction is sample size and therefore statistical
power.
The literature is bedeviled with lack of clear deﬁnition
and measures of PCC in terms of interactions with
health professionals.24 34 35 More frequent use of stan-
dardised and validated measures of PCC in future
research will reduce heterogeneity and allow comparison
between studies on PCC. Further, most studies use self-
reported measures of health behaviours which are
prone to reporting error and bias, as demonstrated by
the lack of consistency between our subjective and
objective assessments. Social desirability bias may be one
explanation for the higher levels of self-reported health
behaviours compared with objective health behaviours
observed in our study. This highlights the need for
future research to include objective measures of out-
comes. Further, we could not exclude reverse causality as
a potential explanation for this and previous ﬁndings.
Future well-conducted trials alongside qualitative work
are essential to explore the mechanism linking PCC,
health behaviours and outcomes. Also, we found stron-
ger associations between PCC among people with poor
glycaemic control, albeit not signiﬁcant. This has been
suggested previously,31 and future research will need to
stratify disease severity and patient groups to further
examine the role of PCC in these particular groups of
patients.
Current National Health Service (NHS) healthcare
policy emphasises the importance of ‘making every
contact count’, and highlights the role that GPs have to
play in modifying health behaviours and secondary
disease risk. Our study provides insufﬁcient evidence to
exclude that PCC is associated with improvements in
health-related behaviours or CVD risk factor levels in the
ﬁrst 5 years following diagnosis. Although PCC is pre-
ferred by our patients and often considered a moral
imperative or the ‘right thing’ for clinicians to do, it is
important to adequately balance PCC against evidence-
based disease management strategies in type 2
diabetes.36
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